Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming David Cullinane .
Filed returns
30
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | Information on a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | AV Room Briefing Event to discuss a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) | 41 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) | 33 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Health | IBD treatment in Ireland (Public policy or programme) | 10 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Health | Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) | 19 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Life Sciences Strategy for Ireland (Public policy or programme) | 10 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Invite to Leinster House briefing on the burden of influenza in Ireland (Public policy or programme) | 15 | On lobbying.ie |
| May–Aug 2024 | Hanover Media Strategy Limited | Health | Event on health landscape in Ireland and Sinn Féin’s health policy priorities. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Hanover Media Strategy Limited | Health | Rare disease policy (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Invitation to a roundtable discussion on the challenges and pressures posed by influenza on the Irish health system, with a particular focus on the over 65s population. (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Introductory meeting (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Introductory meeting (Legislation) | 1 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 23 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Rare Disease Policy (Legislation) | 17 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 18 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Health | Meeting to discuss the reimbursement landscape and access challenges for personalised medicines in Ireland. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Introducing Horizon and its presence in Ireland (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) | 14 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 85 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Provided update to select politicians on developments in Oncology therapies and barriers to access (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 29 | 96.7% | |
| Transport | 1 | 3.3% |